Concurrent gene editing and reprogramming of sickle cell disease fibroblasts using dual measles virus vectors
Research Grant Recipient: Patricia Devaux, PhD
Award Value: $249,998
Research Focus: Gene therapy for sickle cell disease and other inherited blood cell disorders
From the investigator:
We have developed a new technology to reprogram human cells to go back to a state from which they can then develop into other kinds of cells. Our technology is based on a strain of Measles virus, one of the safest vaccines in human history. In this project we will use modify our technology to correct genetic mutation in the human genome and particularly in patients with inherited red blood cell disorders, such as sickle cell disease.